Evidence map›Paper›PMID 41501423›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

In vitro interactions of sulbactam/durlobactam in combination with meropenem, ceftazidime/avibactam, piperacillin/tazobactam, cefiderocol and fosfomycin against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates.

Giulia Zocche, Russell E Lewis, Gabriele Bianco, Carlo Tascini, Paolo Gaibani

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Giulia ZoccheDepartment of Diagnostic and Public Health, Microbiology Section, Verona University, 37134, Verona, Italy.
Russell E LewisDepartment of Molecular Medicine, University of Padova, Padua, 35122, Italy.
Gabriele BiancoDepartment of Experimental Medicine, University of Salento, Lecce, Italy.
Carlo TasciniDepartment of Medicine, Università Degli Studi Di Udine, Udine, Italy.
Paolo GaibaniDepartment of Diagnostic and Public Health, Microbiology Section, Verona University, 37134, Verona, Italy. paolo.gaibani@univr.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated in vitro activity of sulbactam/durlobactam in combination with different antimicrobials against Carbapenem-Resistant Acinetobacter baumannii (CRAB) clinical isolates with different susceptibility profiles, including sulbactam/durlobactam-resistant strains. The genomes of 13 CRAB clinical isolates were characterized by whole-genome sequencing and synergy testing was performed with MIC Test Strips. Sulbactam/durlobactam, when combined with piperacillin/tazobactam or ceftazidime/avibactam, showed synergistic activity against 53.8% (7/13) of CRAB isolates and restored meropenem MIC values below the clinical breakpoint in 46.2% (6/13) of them. Our results demonstrate that sulbactam-durlobactam in combination with β-lactams exhibited high in vitro synergistic activity against CRAB strains.

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsAcinetobacter InfectionsAzabicyclo CompoundsCarbapenemsCefiderocolCeftazidimeCephalosporinsDrug CombinationsDrug Resistance, Multiple, BacterialDrug SynergismFosfomycinHumansMeropenemMicrobial Sensitivity TestsPiperacillin, Tazobactam Drug CombinationAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCarbapenemsCefiderocolCeftazidimeCephalosporinsDrug CombinationsdurlobactamFosfomycinMeropenemPiperacillin, Tazobactam Drug CombinationSulbactamThird Generation CephalosporinsMIC test stripMTS-SAS™Sulbactam/durlobactamSynergy testingWhole-genome

Identifiers

PMID41501423

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.